CHESTER, N.Y.–(BUSINESS WIRE)– Repro Med Systems, Inc. dba RMS Medical Products (OTCQX:REPR) (“RMS Medical”) today announced the appointment of Craig S. Ross as Vice President of Sales and Marketing, effective July 1, 2019. Mr. Ross brings to RMS Medical nearly 25 years of healthcare industry sales, marketing and leadership experience, including more than 20 years of combined experience at Baxalta US (acquired by Shire, now Takeda Pharmaceutical Company), Coram/CVS Specialty Infusion Services, and Schering-Plough.
Mr. Ross’s background includes IV therapies, specialty care, biotechnology, pharmaceuticals, nutrition, supply chain, and healthcare transportation. He has managed annual sales budgets ranging from $65 million to more than $1.0 billion, with responsibilities that include product and service delivery, P&L, private equity, new product launches, M&A, operations, payers, and the regulatory environment. He joins RMS Medical from MedSpeed LLC, a leading US healthcare transportation company operating in 30 states, where he served as Chief Customer Officer.
“We are continuing to build out RMS Medical’s executive team as part of an overall strategy to expand our reach in the industry,” said Don Pettigrew, President and CEO of RMS Medical. “Craig is a seasoned, well-regarded healthcare industry professional who brings a wealth of relevant experience and leadership abilities to RMS Medical. He is operationally driven and has a proven track record of designing and implementing strategies that support growth and build relationships.”
“I am very much looking forward to my new role at RMS Medical,” said Mr. Ross. “The Company has established itself as a leading provider of infusion therapy delivery products and has built a platform upon which we can continue to expand and innovate.”
About RMS Medical Products
RMS Medical develops, manufactures and commercializes innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings. For more information about RMS Medical, please visit www.rmsmedicalproducts.com.
The statements contained herein include prospects, statements of future expectations and other forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties, identified by words such as “believe.” Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements. Factors that may cause actual results to differ materially from current expectations and other risks are discussed in RMS Medical’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K, which filings are available from the SEC and RMS Medical’s website. RMS Medical undertakes no obligation to update any forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190702005361/en/
The Equity Group Inc.
Senior Vice President
Kalle Ahl, CFA
Source: Repro Med Systems, Inc.